

Microbial Fabrication of Silver Nanoparticles: From Biosynthesis to Applications

Amber Chopra, Preeti Pandey* and Priyanka Gupta
Department of Chemistry, Kalinga University, Raipur, CT., India

ABSTRACT

The synthesis of silver nanoparticles (AgNPs) using bacteria has emerged as an attractive, eco-friendly, and cost-effective approach in the field of nanotechnology. This review article comprehensively discusses the diversity of bacteria, including both Gram-positive and Gram-negative strains, capable of producing AgNPs through intracellular and extracellular mechanisms. The characteristics of AgNPs, such as size, shape, and crystallinity, are influenced by the bacterial species and the synthesis conditions. The proposed mechanism of AgNP production involves the reduction of silver ions by bacterial proteins, enzymes, and other biomolecules. The applications of bacterially synthesized AgNPs are vast, encompassing antibacterial, antifungal, antiviral, cytotoxic, antibiofilm, catalytic, and insecticidal activities. The antibacterial activity of AgNPs against various pathogenic bacteria, including antibiotic-resistant strains, is particularly promising. Furthermore, AgNPs exhibit potential in cancer therapy, environmental remediation, and the development of biosensors. Despite the numerous advantages of bacterially synthesized AgNPs, further research is needed to elucidate their long-term effects on human health and the environment. This review highlights the immense potential of bacteria as a sustainable source for AgNP production and their diverse applications, paving the way for future advancements in nanomedicine and biotechnology.

Keywords: bacteria, diversity, extracellular, intracellular, silver nanoparticles (AgNP's)

Correspondence concerning this article should be addressed to Preeti Pandey, E-mail: preeti.pandey@kalingauniversity.ac.in

Competing interests: We declare that there are no conflicts of interest.

Received:18-JAN-2025. Revised: 30-JAN-2025. Accepted & Published: 03-MAR-2025.

INTRODUCTION

Due to their numerous uses in fields such as medicine, electronics, energy, catalysis, biosensors, and good activity against microorganisms, silver nanoparticles (AgNPs) have recently gained significant research attention and growing demand (Kang et al., 2016). According to reports, AgNPs can be produced chemically (using techniques such as microwave-assisted synthesis, microemulsion, pyrolysis, Tollen's method, and electrochemistry), photochemically (using the photo reduction, which is initiated by UV and photoreduction), physically (using techniques such as milling, ablation using lasers, irradiation, and evaporation-condensation), and biologically (using microbes and plants) (Singh et al., 2015). The physiochemical processes necessary for synthesizing AgNPs are costly, time- and energy-intensive, demand extreme temperatures and vacuum environments, and produce harmful by-products that could injure humans and represent a number of dangers to the environment (Borase et al., 2014).

Therefore, given their economic efficacy, safeness, and safety, and contribution to environment sustainability, biological approaches such as the synthesis of AgNPs using greener methods are chosen over the existing approaches (Jayaseelan et al., 2012). The employment of bacteria to synthesize AgNPs is growing among biological methods due to their sustainable behavior, bio-compatible behavior, cost efficacy, benign, and ease of production in large quantities (Law et al., 2008). The first time that *Pseudomonas stutzeri* AG 259, bacteria useful in mining silver that converts ions of silver atoms, that is, AgNP, was reported in literature (Klaus et al., 1999). The aforementioned report encouraged the producing AgNPs by various other bacterial species. The characteristics of several bacteria, including both Gram-positive negative, sequestered from various environments and capable in synthesizing AgNPs have been

presented in Table 1. Current research sheds light on various bacterial genres and strains that are identified to produce AgNPs in terms of characteristics of particles and their uses.

CHARACTERISTICS OF SILVER NANOPARTICLES

AgNPs have several uses and key properties, which creates a strong demand for their manufacturing. The primary distinguishing characteristics of AgNPs are minute sizes (ranging between 1 and 100 nm, that fall between levels of atomic and bulk sizes of materials). The size of the nanoparticles produced during the biogenic production of AgNPs entirely relies on the agents used to cause reduction and the bacterial genre employed. The original bacterium employed for manufacturing AgNPs (sizes of 200 nm) through cultivation in elevated amounts of AgNO₃ was reported as *P. stutzeri* AG259, which was silver-resistant. Similarly, AgNPs obtained from *Bacillus* sp. culture ranged between 5 and 15 nm (Pugazhenthiran et al., 2009). Table 1 shows the diameters of AgNPs formed by several bacterial species. Given that AgNPs have several desirable characteristics, including a large ratio of surface-to-volume, lower melting points, higher superconductivity, higher changeover temperature, low stability of the structure, particular optic properties, and a higher reaction rate, their smaller size is very helpful (Al-Katib et al., 2015).

Table 1: Names of the bacteria that have been found to produce silver nanoparticles (AgNO₃)

Bacteria	Shape	Size (nm)	Location*	Reference
Gram-positive				
<i>Streptomyces</i> sp. 09 PBT 005	spherical	198–595	in-vitro	Saravana Kumar et al. (2015)
<i>Streptomyces</i> sp. SS2	spherical	67.95 ± 18.52	in-vitro	Mohanta and Behera (2014)
<i>Streptomyces kasugaensis</i> M338-M1 ^T	spherical	13.2	in-vitro	Wypij et al. (2017)
<i>Streptomyces celluloflavus</i> NRRL B-2493 ^T				
<i>Streptomyces glaucus</i>	spherical	4–25	in-vitro	Tsibakhashvili et al. (2011)
<i>Streptomyces albidoflavus</i>	NA	10–14	in-vitro	Priyadarshini et al. (2013)
<i>Streptomyces hygroscopicus</i>	spherical	20–30	in-vitro	Sadhasivam et al. (2010)
<i>Pilimelia columellifera</i> subsp. <i>pallida</i>	spherical	12.7–15.9	in-vitro	Golińska et al. (2016)
<i>Sinomonas mesophila</i> MPKL 26	spherical	4–50	in-vitro	Manikprabhu et al. (2016)
<i>Deinococcus radiodurans</i>	spherical	4–50	in-vitro	Kulkarni et al. (2015)
<i>Sporosarcina koreensis</i> DC4	spherical		in-vitro	Singh et al. (2016)
<i>Streptacidiphilus durhamensis</i> HGG16n	spherical	8–48	in-vitro	Buszewski et al. (2018)
<i>Streptacidiphilus</i> sp. CGG11n	spherical	4–45	in-vitro	Railean-Plugaru et al. (2016)
<i>Brevibacterium frigoritolerans</i> strain DC2	spherical	97	in-vitro	Singh et al. (2015)
<i>Bhargavaea indica</i> strain DC1	spherical, triangular, hexagonal,	30–100	in-vitro	Singh et al. (2015)
<i>Weissella oryzae</i> DC6	pentagonal, icosahedral, Spherical	10–30	in-vitro and intracellular	Singh et al. (2016)

Bacteria	Shape	Size (nm)	Location*	Reference
<i>Nocardiopsis valliformis</i> strain OT1	circle	5–50	NA	Rathod et al. (2016)
<i>Staphylococcus aureus</i>	spherical	160–180	in-vitro	Nanda and Saravanan (2009)
<i>Microbacterium resistens</i>	spherical	10–20	in-vitro	Wang et al. (2016)
<i>Rhodococcus</i> sp.	spherical	10–15	intracellular	Otari et al. (2015)
<i>Pedicoccus pentosaceus</i>	NA	NA	intracellular	Sintubin et al. (2009)
<i>Lactobacillus</i> sp.	NA	50	in-vitro and intracellular	Brayner et al. (2007)
<i>L. mindensis</i>	spherical	2–20	in-vitro	Dhoondia and Chakraborty (2012)
<i>Lactococcus lactis</i>	spherical	35	in-vitro	Viorica et al. (2017)
<i>Leuconostoc lactis</i>	spherical	35	in-vitro	Saravanan et al. (2017)
<i>Geobacillus stearothermophilus</i>	spherical	5–50	in-vitro	Mohammed Fayaz et al. (2011)
<i>Exiguobacterium</i> sp.	spherical	10–50	in-vitro	Tamboli and Lee (2013)
<i>Corynebacterium</i> sp. SH09	NA	10–15	in-vitro	Zhang et al. (2005)
<i>Brevibacterium casei</i>	spherical	10–50	in-vitro	Kalishwaralal et al. (2010)
<i>Bacillus</i> sp.	NA	5–15	in-vitro and intracellular	Pugazhenthiran et al. (2009)
<i>Bacillus thuringiensis</i>	NA	43.52–142.97	in-vitro	Banu et al. (2014)
<i>Bacillus subtilis</i>	triangular, hexagonal	20–60	in-vitro	Kannan et al. (2011)
<i>B. subtilis</i>	spherical	60	in-vitro	Kannan et al. (2011)
<i>B. subtilis</i>	spherical	5–60	in-vitro	Sathiyarayanan et al. (2013)
<i>B. subtilis</i> ANR 88	spherical	4–18	in-vitro	Saifuddin et al. (2009)
<i>B. magaterium</i>	hexagonal and cubical	15–50	in-vitro	Rane et al. (2017)
<i>Bacillus cereus</i>	spherical	15	in-vitro	Zaki et al. (2011)
	hexagonal	10–20	in-vitro	Prakash, et al. (2011)
<i>B. methylotrophicus</i>	spherical	10–30	in-vitro	Pourali and Yahyaei (2016)
<i>Bacillus pumilus</i>	spherical	77–92	in-vitro	Wang et al. (2016)
<i>Bacillus licheniformis</i>	spherical	18.69–63.42	in-vitro	Elbeshehy et al. (2015)
<i>Bacillus stearothermophilus</i>	spherical	14 ± 4	in-vitro	Shanthi et al. (2016)
<i>B. thuringiensis</i>	NA	20–40	in-vitro	El-Batal et al. (2013)
<i>S. aureus</i>				
<i>Staphylococcus epidermidis</i>	spherical, oval, rod, and triangular	<60	intracellular	Verma et al. (2018)
	Spherical		in-vitro	

Bacteria	Shape	Size (nm)	Location*	Reference
<i>Streptococcus thermophiles</i>		28–122		Rezvani Amin et al. (2016)
<i>Thermoactinomyces</i> sp.	spherical	20–40	in-vitro	El-Shanshoury et al. (2011)
<i>Ureibacillus thermosphaericus</i>	spherical	10–100	in-vitro	Deepa et al. (2013)
<i>Nocardiopsis</i> sp. MBRC-1	spherical	45 ± 0.15	in-vitro	Juibari et al. (2011)
<i>Arthrobacter</i> sp. B4	face-centered cubic	9–72	in-vitro	Manivasagan et al. (2013)
Gram-negative				
<i>Pseudomonas deceptionensis</i> DC5	spherical	127	in-vitro	Yumei et al. (2017)
<i>Pseudomonas aeruginosa</i>	spherical, disc shaped	6.3 ± 4.9	in-vitro and intracellular	Jo et al. (2016)
	spherical	8–24		
	quasispherical	5–25		
<i>P. aeruginosa</i> BS-161R	spherical	13	in-vitro	Srivastava and Constanti (2012)
<i>P. aeruginosa</i> ATCC 27853	spherical	33–300	in-vitro	Kumar and Mamidyala (2011)
<i>P. aeruginosa</i>	spherical	25–45	in-vitro	Peiris et al. (2017)
	pseudospherical			
<i>P. aeruginosa</i> SN5	NA	35–60	in-vitro	Quinteros et al. (2016)
<i>P. aeruginosa</i> DM1	spherical	45–100	in-vitro	Naik et al. (2017)
	face-centered cubic			
<i>Pseudomonas</i> sp.	variable	50	in-vitro	Kumari et al. (2017)
Endosymbiont <i>Pseudomonas fluorescens</i> CA 417	face-centered cubic	5–50	in-vitro	Ali et al. (2016) and Punjabi et al. (2017)
<i>Escherichia coli</i>	spherical	20–50	in-vitro	Syed et al. (2016)
<i>E. coli</i>	spherical	42.2–89.6	in-vitro	Kushwaha et al. (2015)
		15.0 ± 7.6		
<i>Novosphingobium</i> sp. THG-C3	spherical	8–25	NA	Chumpol and Siri (2017)
<i>Ochrobactrum anthropi</i> strain PH5	spherical	35–85	intracellular	Du et al. (2016) and Gahlawat et al. (2016)
		10		
<i>O. rhizosphaerae</i>				
<i>Bradyrhizobium japonicum</i> 36	rod and oval	5–50	NA	Thomas et al. (2014)
<i>Proteus mirabilis</i>	spherical	10–20	in-vitro and intracellular	Rasulov et al. (2016)
<i>Moganella</i> sp.	quasi-spherical	10–40	in-vitro	Samadi et al. (2009)

Bacteria	Shape	Size (nm)	Location*	Reference
<i>Klebsiella pneumonia</i>	spherical	15–37 5–32	in-vitro	Parikh et al. (2011)
<i>Klebsiella oxytoca</i> DSM 29614	spherical	NA	in-vitro	Kalpana and Lee (2013)
<i>Idiomarina</i> sp.	NA	25	intracellular	Baldi et al. (2016)
<i>Gluconobacter roseus</i>	NA	10	in-vitro	Seshadri et al. (2012)
<i>Geobacter sulfurreducens</i>	NA	NA	in-vitro	Singh et al. (2016)
<i>Enterobacter aerogenes</i>	spherical	25–35	in-vitro	Krishnaraj and Berchmans (2013)
<i>Aeromonas</i> sp.	face-centered cubic spherical	6.4 8–16	in-vitro and intracellular	Karthik and Radha (2012)
<i>Xanthomonas oryzae</i>	spherical, triangular, and rod shape	14.86	in-vitro	Singh et al. (2017)

*in-vitro or intracellular

The melting temperature drops because of the higher surface-to-volume ratios, as the liquid/vapor interface energy is lower due to the small crystal size compared to the average solid/vapor interface energy.

AgNPs are reported to be single-phased, crystalline, and have FCC symmetry, as reported by an X-ray diffraction structural investigation (Mulvaney, 1996). They come in various colors and shapes, such as spheres, rods, ovals, hexagons, cubes, and pseudospherical (Table 1) (Kulkarni et al., 2015; Wypij et al., 2017).

COMPARISON OF INTRACELLULAR AND EXTRACELLULAR SYNTHESIS OF $AgNO_3$

According to reports, depending on where the reduction of silver ions takes place, bacteria can be produced by nanoparticles on the in-cell (intracellular), *in vitro* (extracellular), or even by both ways (Table 1).

Extracellular Synthesis

In the extracellular synthesis of $AgNO_3$, Ag^+ ions are broken down by bacteria into their rudimentary form (Ag^0) that builds on the outside of the cell and produces AgNPs. Concerning the media used for culturing bacteria, AgNPs are produced extracellularly, and the resulting nanoparticles can have different shapes, such as triangles, spheres, hexagons, circles, ovals, cubes, or disks (Nanda & Saravanan, 2009; Otari et al., 2015). In cases of biogenous reduction, the agent used for reducing Ag^+ to Ag^0 is either a tiny soluble secreted enzyme or a protein found on the bacterial cell wall. Functional characterization of the different bacterial genre that produces AgNPs extracellularly in the environment (Table 1). *Aeromonas* sp. SH10's dry mass of the cell converts Ag^+ to Ag^0 and releases it in the medium. *Bacillus licheniformis*, *B. pumilus*, and *Bacillus persicus* can produce AgNPs with sizes of 72–92 nm on the cell's exterior (Elbeshehy et al., 2015). AgNPs produced extracellularly can be quickly recovered using centrifugation at a high speed of about 10–12 thousand revolutions per minute, where they are collected and preserved in the form of a pellet that can be redissolved in other solvents of choice. As a result, they are at the top of their game for several purposes and are used in fields such as optronics, electronics, automation, imaging, and sensors (Benn & Westerhoff, 2008).

Intracellular Synthesis

Transport of silver ions in the interior of bacteria is a component of the intracellular creation of AgNPs and is aided by membrane proteins. Some silver-resistant bacteria limit silver salts' harmful effects by converting Ag^+ to Agdegrees, which builds up either in the periplasm or on the cell's wall. According to reports, the amount of Agdegrees accumulated on bacterial cell walls can account for up to 25% of their mass. AgNO_3 solution is reduced by *P. stutzeri* AG259, yielding 200 nm AgNPs and a minor amount of crystalline with monoclinic form Ag sulfide acanthite (Ag_2S) (Klaus et al., 1999). Similar to this, *Corynebacterium* sp. SH09 can produce AgNPs, which form a diamine Ag combination on cell walls and range in size from 10 to 15 nm (Verma et al., 2018). Additional procedures are needed to recover the AgNPs created inside the cell, such as bacterial cell lysis using a physical approach (ultrasonication), a thermal method (autoclaving), or a chemical way (application of salts and detergents) (Fesharaki et al., 2010). Notably, some bacteria, such as *P. mirabilis* and *Vibrio alginolyticus*, produce AgNPs made by intracellular and extracellular mechanisms depending on the media used for growth (Samadi et al., 2009). In the media and the periplasm, AgNPs (5–15 nm) were reported to have been produced by *Bacillus* species by Pugazhenthiran et al. (2009)

MECHANISM OF AGNP PRODUCTION

Bacteria have a genetic and biochemical process, for tolerating extreme circumstances of the environment and surviving in the environment when exposed to various environmental parameters (temperature, pH, and salt concentration).

The level to which Ag salts can cause toxicity can be assessed from diverse methods contingent on the type of bacteria (Buszewski et al., 2018). Specific strains of *E. coli* can resist Ag ions by giving out ions out of the cell; by contrast, some reduce the harmful effects of Ag ions by breaking them to their rudimentary form and creating AgNPs. Agdegrees build up inside the cell by *P. stutzeri*'s reduction of Ag ions from Ag^+ to Agdegrees. Even though the decisive process of AgNP generation by the bacteria is still not understood, numerous ideas have been proposed to explain the function of bacterial proteins or enzymes and genes (Railean-Plugaru et al., 2016). AgNPs are synthesized by bacteria using bottom-up processes that start with small entities like atoms and molecules and end with reduced oxidation reactions (Figure 1) in the biogenous reduction of silver ions at or near ambient pressure, temperature, and pH. The mechanism entails crystal stability, capping, reduction, and entrapment of silver ions. There must be a source for internal or extracellular syntheses that requires trapping the silver ions. According to some theories (Law et al., 2008; Singh et al., 2015), Given intracellular synthesis, silver ions can be brought into the cell for reduction into rudimentary silver. According to several investigations, the cell wall's proteins and carbohydrates play a significant part in the entrapment of silver ions, where the bio-reduction process can occur (Kalishwaralal et al., 2010). Owing to the existence of carboxylate groups, most bacterial cell surfaces have a negative charge, It is understood that electrostatic relations among the positively charged Ag ions and the negatively charged carboxylate ions on the surface cause the Ag ions to be entrapped on the cell surface. The active symport of Na^+ and Ag ions from the region of the extracellular environment reduces the transmembrane proton pitch produced by some bacteria. The take up of silver ions within the cell and the beginning of AgNP synthesis are caused by some proteins forming the silver-binding membrane, which draws silver ions and consumes the energy released during the ATP hydrolysis to do so. When extracellular synthesis occurs, the cell secretes extracellular polymeric compounds made of proteins and polysaccharides that can cling to and trap ions. Reducers such as proteins, enzymes, carbohydrates, and amino acids—also produced from the cells—break down the trapped ions outside the cells (Oves et al., 2013). Several studies indicate that NADH-dependent reductase is a must-situation for creating silver nanoparticles (AgNPs), where NADH- H^+ contributes its electrons to silver ions, which are then reduced to their elemental form and build up as AgNPs. It has been noted that some bacteria, including *Acinetobacter* sp., use nitrate reductase as a reducing agent in the manufacture of AgNPs (Singh et al., 2015). AgNO_3 has been reported to be reduced to AgNPs by nitroreductase A (Nfsa), an oxygen-insensitive nitroreductase enzyme found in

Enterobacteriaceae. Peptides with disulfide connections may also be employed to decrease Ag^+ to Ag^0 . Some amino acids, including arginine, aspartic acid, cysteine, glutamic acid, lysine, and methionine, play a role in the reduction of silver ions or silver nanocrystals that function as catalysts by generating hydroxyl ions that interact with reducing agents like aldehyde. The synthesis of AgNPs by bacteria depends on a number of variables, including a high pH and a partial pressure of H_2 gas. The activation of the reductase subunit of the oxidoreductase enzyme is significantly influenced by high pH. Silver ions are also converted to AgNPs by the semiquinone structure created from tyrosine in an alkaline environment through the ionization of phenol groups. Open-chain aldehydes oxidize with Ag^+ ions to produce a corresponding carboxylic acid and accumulate AgNPs to avoid agglomeration in an alkaline situation. Tryptophan is transformed into the transitory tryptophyl radical at high pH levels, contributing electrons to the silver ions and reducing them to elemental silver. In particular, protein cell walls stabilize silver nanoparticles and prevent silver ions from penetrating any surfaces.




Figure 1. Production of silver nanoparticles (AgNO_3) by bacteria assisted NADH- dependent nitrate reductase enzyme

APPLICATION OF SILVER NANOPARTICLES IN DIFFERENT FIELDS

Due to its environmentally benign production process and distinctive physical and chemical features, the manufacture of biological AgNP has received enormous research attention and importance. AgNPs have a variety of uses, including cytotoxicity, antibacterial and antifungal properties, biosensors, and catalysis (Borase et al., 2014). The following categories—which have all been thoroughly examined and discussed—cover the different uses of AgNPs (Figure 2).

Antibacterial Activities

The antibacterial action of AgNPs synthesized through bacteria has been seen in the literature (Nanda & Saravanan, 2009; Saravana Kumar et al., 2015; Singh et al., 2015; Singh et al., 2015). AgNPs have been seen to have good antibacterial action against a variety of bacteria which are both Gram-positive and negative, like *Bacillus subtilis*, *B. cereus*, *Enterococcus hirae*, *S. aureus*, *S. epidermidis*, and *Streptococcus pyogenes* and *E. coli*, *Klebsiella planticola*, *Klebsiella pneumoniae*, *Proteus vulgaris*, *P. aeruginosa*, *Salmonella* sp., *Shigella flexneri*, and *Vibrio cholerae* (Nanda & Saravanan, 2009; Saravana Kumar et al., 2015). The nontoxic properties and improved antibacterial activity of AgNPs against pathogenic bacteria is attributed to their minute sizes and higher surface zone (Nanda & Saravanan, 2009). The best bactericidal activity was demonstrated by AgNPs of size 5 nm against *S. aureus* NCIM 5,201, *B. subtilis* MTCC 441, and *E. coli* MTCC 443. The benefit of AgNPs' tiny size is that they may quickly enter bacterial cells (Gahlawat et al., 2016). AgNPs have a strong affinity for sulfur, phosphorus, proteins, and DNA, which

makes it likely that these nanoparticles will attack these molecules. Upon entering the center of the cell, AgNPs create high-molecular-weight regions; however, due to the electron transport chain, bacterial cells congest by shielding their DNA from AgNPs. During the division of the cell, Ag ions released from AgNP's affects the bacteria, causing the death of the cell.




Figure 2. Utilization of silver nanoparticles in various applications

Shrinking of the cytoplasmic membrane, denaturation of proteins, inhibition in uptake or absorption of phosphate, release of potassium ions in cells of bacteria, glucose inhibition, oxidation of succinate, glycerol, and fumarate, and enzyme inactivity by formation of complex with functional group of electron donor upon the residues of amino acids and DNA are the other ways in which AgNP's show their antibacterial activity.

Antifungal Activity

AgNPs generated in-vitro or intracellularly possess antifungal properties, according to a number of investigations (Gajbhiye et al., 2009). The antifungal characteristic of AgNPs could be linked to the oligo dynamicity that manifests changes in permeable characteristics of the cell membrane, protein denaturation, and suppression of replicating ability of DNA. AgNPs' wide surface area aids in more significant contact with the fungus. The activity of AgNPs against numerous species of fungus was evaluated, and it was seen to have good activity in comparison to existing conventional antibiotics like *Phoma glomerata*, *Phoma herbarum*, *Fusarium semitectum*, *Trichoderma* sp., and *Candida albicans* (Gajbhiye et al., 2009). AgNPs produced utilizing reducing agents and stabilizers have been discovered to increase the activities of various antifungal medicines, including fluconazole, which demonstrates inhibitory activity against *C. albicans*, *P. glomerata*, and *Trichoderma* sp. (Gajbhiye et al., 2009). Extracellularly produced AgNP particles with sizes of 27 nm exhibited antifungal efficacy against *Fusarium oxysporum*. Consequently, the discovery and design of medicines will benefit from this valuable complete information on the wide range of silver nanoparticles made by bacteriologically synthesizing silver in the forthcoming years.

Cytotoxicity

Biogenic AgNPs were discovered to be harmful to various cell lines in applications of nanoparticles in the biomedicines field by various mechanisms, including rupture of mitochondrial membrane, alterations or inductions in apoptosis, and induced damage of DNA (Singh et al., 2015). The antiproliferative action of AgNPs is used in the chemotherapy of malignant cells with various responses, which may be caused by

AgNPs interfering with functions of proteins like protein aggregation and unfolding and cellular chemistry induction. AgNPs were hazardous to the MDA-MB-231 human breast cancer line of cells and NIH-3T3 mouse embryonic fibroblast, leading to cellular effects such as cytotoxicity, genotoxicity induction, morphology modification, and oxidation stress. The concentration of AgNPs employed determines the cytotoxicity of AgNPs on cells. AgNPs were evaluated for their cytotoxicity at various concentrations, and it could be seen that at 50 g/ml, AgNPs had no discernible effect on cell viability. However, at 1,000 g/ml, cell viability was considerably reduced.

Antibiofilm Activity

About 80% of microbial illnesses in people are brought on by biofilm, a stratum of proteins, polysaccharides, and DNA formed via microorganisms on their own. The utilization of nanoparticles in treating biofilm-related illnesses is well documented in various papers. AgNPs could cause a significant reduction in the formation of *P. aeruginosa* and *S. epidermidis* biofilms. According to the reports by Kalishwaralal et al. (2010), AgNPs were effective and significantly reduced *S. epidermidis* and *P. aeruginosa* biofilms. AgNPs could penetrate the biofilms of bacteria and prevent the formation of glycocalyx matrix and adhesion of bacteria. AgNPs can infiltrate into bacterial biofilms and release silver ions without getting disrupted or detached, and they present a more excellent surface-to-mass ratio. AgNPs and antibiotics may be a beneficial combination for eliminating the biofilms. Mu et al. (2016) put forward a synergetic method, which reported using gentamicin-enriched AgNPs to prevent the growth of new biofilms and dislodge existing ones.

Catalytic Activity

Organic pollutants in the Environment that are produced in the form of effluents in the plastic, textile, and other sectors pose a serious threat to land-dwelling and marine ecosystems and are resilient to remediation's that are physicochemical remediation. For their catalytic activity in reducing organic molecules like colors and pollutants to less hazardous chemicals, AgNPs have been investigated (Fesharaki et al., 2010). The effectiveness of AgNPs in decreasing the amount of bond dissociation energy between methylene blue, an organic dye, and sodium borohydride within a few hours of exposure shows that they have catalytic activity. In the presence of sodium borohydride, it has been discovered that AgNPs catalyze the reduction of 4-nitrophenol. AgNPs are beneficial in processes such as recycling due to the structure of pores, geometries (shapes and sizes), reasonable specificity and selectivity, and good surface areas. Silver nanoparticles were used to demonstrate the photocatalytic degradation of contaminants into benign compounds. This might be explained by surface plasmon resonance, which enhances water-repelling characteristics and dissociation while preventing graphene sheet aggregation. When compared to traditional catalysts, the use of biogenous silver nanoparticles for applications that need catalytic activity is more efficient, cost-effective, and environmentally benign, providing a viable option for the biological degradation and biological remediation of contaminants in the environment.

Antiviral Property

AgNPs have exhibited antiviral action with the hepatitis B virus, herpes simplex virus, monkeypox virus, influenza virus, and HIV. AgNPs can stimulate chemokines and cytokines synthesis that inter-react with exposed glycoprotein knob that contains sulfur for prevention of viral attachment and infiltration, reduce TNF- expression, and transcription inhibition, all of which are crucial for the pathogenesis of HIV-1. At the beginning of viral reproduction, AgNPs act as virucidal or inhibitors of viruses that are resistant to mutation and independent of cell tropism determinants. AgNPs attach to protein structures surrounding the viral membrane, preventing the interaction of HIV-1 envelop glycoprotein (gp120-CD4) necessary for viral entry and causing denaturation of proteins (Borkow & Lapidot, 2005).

Other Applications

Pesticides are a vital part of pest management and control, although using chemically synthesized insecticides is unsuccessful since insects have developed resistance to them. Nanotechnology is considered one of the most favorable methods for controlling insects and other pests because of its nontoxic characteristics, increased infiltrating power, huge surface capacity, and remarkable forte. AgNPs can kill mosquito larvae by clustering together, piercing the larval membrane, and attaching to proteins or DNA that contain sulfur. This results in the denaturation of enzymes and cell organelles (Fesharaki et al., 2010). AgNPs have been reported to be efficacious against maggots of *Aedes aegypti* and *Anopheles stephensi* (Borkow & Lapidot, 2005). AgNPs are also significant in applications, including cosmetics, antimicrobial mediators, food-packing, coatings, textiles, bio-medicals, and wound-healing processes (Borkow & Lapidot, 2005).

CONCLUSIONS AND FUTURE DIRECTIONS

The growing emphasis on green chemistry has driven the development of environmentally friendly methods for silver nanoparticle (AgNP) production. This review has highlighted the various biological sources for AgNP synthesis and their most promising applications in environmental processes and medical devices. The utilization of microorganisms for green synthesis of AgNPs represents an innovative frontier in nanotechnology with significant potential to shape future developments in nanoscience.

Analysis of the scientific literature reveals that studies on AgNP applications have predominantly been conducted in vitro, with limited reports of their application in living systems. In vivo studies provide considerably less information regarding potential mechanisms of AgNP toxicity compared to in vitro research. While the applications of AgNPs are expected to expand, additional data concerning their environmental accumulation and potential long-term effects on humans and animals remains essential.

Despite the promising advantages of bacterially synthesized AgNPs, comprehensive research is still needed to elucidate their long-term impacts on human health and environmental systems. Bacteria represent a sustainable resource for AgNP production, with diverse applications that show significant potential for advancement in nanomedicine and biotechnology. We anticipate that biosynthesized AgNPs will soon establish new pathways for various biomedical applications such as nanodrugs.

REFERENCES

- Ali, J., Hameed, A., Ahmed, S., Ali, M. I., Zainab, S., & Ali, N. (2016). Role of catalytic protein and stabilising agents in the transformation of Ag ions to nanoparticles by *Pseudomonas aeruginosa*. *IET Nanobiotechnology*, 10(5), 295–300. <https://doi.org/10.1049/iet-nbt.2015.0093>
- Al-Katib, M., Al-Shahri, Y., & Al-Niemi, A. (2015). Biosynthesis of silver nanoparticles by *Cyanobacterium Gloeocapsa* sp. *International Journal of Enhanced Research in Science, Technology & Engineering*, 4(9), 60–73.
- Baldi, F., Daniele, S., Gallo, M., Paganelli, S., Battistel, D., Piccolo, O., Faleri, C., Puglia, A. M., & Gallo, G. (2016). Polysaccharide-based silver nanoparticles synthesized by *Klebsiella oxytoca* DSM 29614 cause DNA fragmentation in *E. coli* cells. *Biometals*, 29(2), 321–331. <https://doi.org/10.1007/s10534-016-9918-4>
- Banu, A. N., Balasubramanian, C., & Moorthi, P. V. (2014). Biosynthesis of silver nanoparticles using *Bacillus thuringiensis* against dengue vector, *Aedes aegypti* (Diptera: Culicidae). *Parasitology Research*, 113(1), 311–316. <https://doi.org/10.1007/s00436-013-3656-0>
- Benn, T. M., & Westerhoff, P. (2008). Nanoparticle silver released into water from commercially available sock fabrics. *Environmental Science and Technology*, 42(11), 4133–4139. <https://doi.org/10.1021/es7032718>
- Borase, H. P., Salunke, B. K., Salunkhe, R. B., Patil, C. D., Hallsworth, J. E., Kim, B. S., & Patil, S. V. (2014). Plant extract: A promising Biomatrix for ecofriendly, controlled synthesis of silver nanoparticles. *Applied Biochemistry and Biotechnology*, 173(1), 1–29. <https://doi.org/10.1007/s12010-014-0831-4>
- Borkow, G., & Lapidot, A. (2005). Multi-targeting the entrance door to block HIV-1. *Current Drug Targets. Infectious Disorders*, 5(1), 3–15. <https://doi.org/10.2174/1568005053174645>

- Brayner, R., Barberousse, H., Hemadi, M., Djedjat, C., Yéprémian, C., Coradin, T., Livage, J., Fiévet, F., & Couté, A. (2007). Cyanobacteria as bioreactors for the synthesis of Au, Ag, Pd, and Pt nanoparticles via an enzyme-mediated route. *Journal of Nanoscience and Nanotechnology*, 7(8), 2696–2708. <https://doi.org/10.1166/jnn.2007.600>
- Buszewski, B., Railean-Plugaru, V., Pomastowski, P., Rafińska, K., Szultka-Mlynska, M., Golinska, P., Wypij, M., Laskowski, D., & Dahm, H. (2018). Antimicrobial activity of biosilver nanoparticles produced by a novel *Streptacidiphilus durhamensis* strain. *Journal of Microbiology, Immunology, and Infection*, 51(1), 45–54. <https://doi.org/10.1016/j.jmii.2016.03.002>
- Chumpol, J., & Siri, S. (2017). Simple green production of silver nanoparticles facilitated by bacterial genomic DNA and their antibacterial activity. *Artificial Cells, Nanomedicine and Biotechnology*, 1–7, Article 1332638. <https://doi.org/10.1080/21691401.2017>
- Deepa, S., Kanimozhi, K., & Panneerselvam, A. (2013). Antimicrobial activity of extracellularly synthesized silver nanoparticles from marine derived actinomycetes. *International Journal of Current Microbiology and Applied Sciences*, 2, 223–230.
- Dhoondia, Z. H., & Chakraborty, H. (2012). Lactobacillus mediated synthesis of silver oxide nanoparticles. *Nanomaterials and Nanotechnology*, 2, 1–7.
- Du, J., Singh, H., & Yi, T.-H. (2017). Biosynthesis of silver nanoparticles by *Novosphingobium* sp. THG-C3 and their antimicrobial potential. *Artificial Cells, Nanomedicine, and Biotechnology*, 45(2), 211–217. <https://doi.org/10.1080/21691401.2016.1178135>.
- El-Batal, A. I., Hashem, A.-A. M., & Abdelbaky, N. M. (2013). Gamma radiation mediated green synthesis of gold nanoparticles using fermented soybean-garlic aqueous extract and their antimicrobial activity. *SpringerPlus*, 2(1), 129. <https://doi.org/10.1186/2193-1801-2-129>
- Elbeshehy, E. K. F., Elazzazy, A. M., & Aggelis, G. (2015). Silver nanoparticles synthesis mediated by new isolates of *Bacillus* spp., nanoparticle characterization and their activity against bean yellow mosaic virus and human pathogens. *Frontiers in Microbiology*, 6, 453. <https://doi.org/10.3389/fmicb.2015.00453>
- El-Shanshoury, A. E.-R. R., ElSilk, S. E., & Ebeid, M. E. (2011). Extracellular biosynthesis of silver nanoparticles using *Escherichia coli* ATCC 8739, *Bacillus subtilis* ATCC 6633, and *Streptococcus thermophilus* ESh1 and their antimicrobial activities. *ISRN Nanotechnology*, 2011, 1–7. <https://doi.org/10.5402/2011/385480>
- Fesharaki, P. J., Nazari, P., Shakibaie, M., Rezaie, S., Banooe, M., Abdollahi, M., & Shahverdi, A. R. (2010). Biosynthesis of Selenium nanoparticles using *Klebsiella pneumoniae* and their recovery by a simple sterilization process. *Brazilian Journal of Microbiology*, 41(2), 461–466. <https://doi.org/10.1590/S1517-838220100002000028>
- Gahlawat, G., Shikha, S., Chaddha, B. S., Chaudhuri, S. R., Mayilraj, S., & Choudhury, A. R. (2016). Microbial glycolipoprotein-capped silver nanoparticles as emerging antibacterial agents against cholera. *Microbial Cell Factories*, 15, 25. <https://doi.org/10.1186/s12934-016-0422-x>
- Gajbhiye, M., Kesharwani, J., Ingle, A., Gade, A., & Rai, M. (2009). Fungus-mediated synthesis of silver nanoparticles and their activity against pathogenic fungi in combination with fluconazole. *Nanomedicine*, 5(4), 382–386. <https://doi.org/10.1016/j.nano.2009.06.005>
- Golińska, P., Wypij, M., Rathod, D., Tikar, S., Dahm, H., & Rai, M. (2016). Synthesis of silver nanoparticles from two acidophilic strains of *Pilimelia columellifera* subsp. *pallida* and their antibacterial activities. *Journal of Basic Microbiology*, 56(5), 541–556. <https://doi.org/10.1002/jobm.201500516>
- Govindaraju, K., Basha, S. K., Kumar, V. G., & Singaravelu, G. (2008). Silver, gold and bimetallic nanoparticles production using single-cell protein (*Spirulina platensis*) Geitler. *Journal of Materials Science*, 43(15), 5115–5122. <https://doi.org/10.1007/s10853-008-2745-4>
- Jayaseelan, C., Rahuman, A. A., Kirthi, A. V., Marimuthu, S., Santhoshkumar, T., Bagavan, A., Gaurav, K., Karthik, L., & Rao, K. V. B. (2012). Novel microbial route to synthesize ZnO nanoparticles using *Aeromonas hydrophila* and their activity against pathogenic bacteria and fungi. *Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy*, 90, 78–84. <https://doi.org/10.1016/j.saa.2012.01.006>
- Jo, J. H., Singh, P., Kim, Y. J., Wang, C., Mathiyalagan, R., Jin, C.-G., & Yang, D. C. (2016). *Pseudomonas deceptionensis* DC5-mediated synthesis of extracellular silver nanoparticles. *Artificial Cells, Nanomedicine, and Biotechnology*, 44(6), 1576–1581. <https://doi.org/10.3109/21691401.2015.1068792>
- Juibari, M. M., Abbasalizadeh, S., Jouzani, G. S., & Noruzi, M. (2011). Intensified biosynthesis of silver nanoparticles using a native extremophilic *Ureibacillus thermosphaericus* strain. *Materials Letters*, 65(6), 1014–1017. <https://doi.org/10.1016/j.matlet.2010.12.056>

- Kalishwaralal, K., Deepak, V., Ram Kumar Pandian, S., Kottaisamy, M., BarathmaniKanth, S., Kartikeyan, B., & Gurunathan, S. (2010). Biosynthesis of silver and gold nanoparticles using *Brevibacterium casei*. *Colloids and Surfaces. B, Biointerfaces*, 77(2), 257–262. <https://doi.org/10.1016/j.colsurfb.2010.02.007>
- Kalpana, D., & Lee, Y. S. (2013). Synthesis and characterization of bactericidal silver nanoparticles using cultural filtrate of simulated microgravity grown *Klebsiella pneumoniae*. *Enzyme and Microbial Technology*, 52(3), 151–156. <https://doi.org/10.1016/j.enzmictec.2012.12.006>
- Kang, Y. O., Jung, J.-Y., Cho, D., Kwon, O. H., Cheon, J. Y., & Park, W. H. (2016). Antimicrobial silver chloride nanoparticles stabilized with chitosan oligomer for the healing of burns. *Materials*, 9(4), 215. <https://doi.org/10.3390/ma9040215>
- Kannan, N., Mukunthan, K. S., & Balaji, S. (2011). A comparative study of morphology, reactivity and stability of synthesized silver nanoparticles using *Bacillus subtilis* and *Catharanthus roseus* (L.) G. Don. *Colloids and Surfaces. B, Biointerfaces*, 86(2), 378–383. <https://doi.org/10.1016/j.colsurfb.2011.04.024>
- Karthik, C., & Radha, K. V. (2012). Biosynthesis and characterization of silver nanoparticles using *Enterobacter aerogenes*: A kinetic approach. *Digest Journal of Nanomaterials and Biostructures*, 7, 1007–1014.
- Klaus, T., Joerger, R., Olsson, E., & Granqvist, C. G. (1999). Silver-based crystalline nanoparticles, microbially fabricated. *Proceedings of the National Academy of Sciences of the United States of America*, 96(24), 13611–13614. <https://doi.org/10.1073/pnas.96.24.13611>
- Krishnaraj, R. N., & Berchmans, S. (2013). In vitro antiplatelet activity of silver nanoparticles synthesized using the microorganism *Gluconobacter roseus*: An AFM-based study. *RSC Advances*, 3(23), 8953–8959. <https://doi.org/10.1039/c3ra41246f>
- Kulkarni, R. R., Shaiwale, N. S., Deobagkar, D. N., & Deobagkar, D. D. (2015). Synthesis and extracellular accumulation of silver nanoparticles by employing radiation-resistant *Deinococcus radiodurans*, their characterization, and determination of bioactivity. *International Journal of Nanomedicine*, 10, 963–974. <https://doi.org/10.2147/IJN.S72888>
- Kumar, C. G., & Mamidyala, S. K. (2011). Extracellular synthesis of silver nanoparticles using culture supernatant of *Pseudomonas aeruginosa*. *Colloids and Surfaces. B, Biointerfaces*, 84(2), 462–466. <https://doi.org/10.1016/j.colsurfb.2011.01.042>
- Kumari, R., Barsainya, M., & Singh, D. P. (2017). Biogenic synthesis of silver nanoparticle by using secondary metabolites from *Pseudomonas aeruginosa* DM1 and its anti-algal effect on *Chlorella vulgaris* and *Chlorella pyrenoidosa*. *Environmental Science and Pollution Research International*, 24(5), 4645–4654. <https://doi.org/10.1007/s11356-016-8170-3>
- Kushwaha, A., Singh, V. K., Bhartariya, J., Singh, P., & Yasmeen, K. (2015). Isolation and identification of *E. coli* bacteria for the synthesis of silver nanoparticles: Characterization of the particles and study of antibacterial activity. *European Journal of Experimental Biology*, 5(1), 65–70.
- Law, N., Ansari, S., Livens, F. R., Renshaw, J. C., & Lloyd, J. R. (2008). Formation of nanoscale elemental silver particles via enzymatic reduction by *Geobacter sulfurreducens*. *Applied and Environmental Microbiology*, 74(22), 7090–7093. <https://doi.org/10.1128/AEM.01069-08>
- Manikprabhu, D., Cheng, J., Chen, W., Sunkara, A. K., Mane, S. B., Kumar, R., Das, M., N Hozzein, W., Duan, Y.-Q., & Li, W.-J. (2016). Sunlight mediated synthesis of silver nanoparticles by a novel actinobacterium (*Sinomonas mesophila* MPKL 26) and its antimicrobial activity against multi drug resistant *Staphylococcus aureus*. *Journal of Photochemistry and Photobiology. B, Biology*, 158, 202–205. <https://doi.org/10.1016/j.jphotobiol.2016.01.018>
- Manivasagan, P., Venkatesan, J., Senthilkumar, K., Sivakumar, K., & Kim, S.-K. (2013). Biosynthesis, antimicrobial and cytotoxic effect of silver nanoparticles using a novel *Nocardia* sp. MBRC-1. *BioMed Research International*, 2013, Article 287638. <https://doi.org/10.1155/2013/287638>
- Mohammed Fayaz, A., Girilal, M., Rahman, M., Venkatesan, R., & Kalaiichelvan, P. T. (2011). Biosynthesis of silver and gold nanoparticles using thermophilic bacterium *Geobacillus stearothermophilus*. *Process Biochemistry*, 46(10), 1958–1962. <https://doi.org/10.1016/j.procbio.2011.07.003>
- Mohanta, Y. K., & Behera, S. K. (2014). Biosynthesis, characterization and antimicrobial activity of silver nanoparticles by *Streptomyces* sp. SS2. *Bioprocess and Biosystems Engineering*, 37(11), 2263–2269. <https://doi.org/10.1007/s00449-014-1205-6>
- Mu, H., Tang, J., Liu, Q., Sun, C., Wang, T., & Duan, J. (2016). Potent antibacterial nanoparticles against biofilm and intracellular bacteria. *Scientific Reports*, 6, Article 18877. <https://doi.org/10.1038/srep18877>
- Mulvaney, P. (1996). Surface plasmon spectroscopy of nanosized metal particles. *Langmuir*, 12(3), 788–800. <https://doi.org/10.1021/la9502711>
- Naik, M. M., Prabhu, M. S., Samant, S. N., Naik, P. M., & Shirodkar, S. (2017). Synergistic action of silver nanoparticles synthesized from silver resistant estuarine *Pseudomonas aeruginosa* strain SN5 with antibiotics against antibiotic resistant

- bacterial human pathogens. *Thalassas: An International Journal of Marine Sciences*, 33(1), 73–80. <https://doi.org/10.1007/s41208-017-0023-4>
- Nanda, A., & Saravanan, M. (2009). Biosynthesis of silver nano- particles from *Staphylococcus aureus* and its antimicrobial activity against MRSA and MRSE. *Nanomedicine: Nanotechnology, Biology, and Medicine*, 5(4), 452–456. <https://doi.org/10.1016/j.nano.2009.01.012>
- Otari, S. V., Patil, R. M., Ghosh, S. J., Thorat, N. D., & Pawar, S. H. (2015). Intracellular synthesis of silver nanoparticle by Actinobacteria and its antimicrobial activity. *Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy*, 136(B), 1175–1180. <https://doi.org/10.1016/j.saa.2014.10.003>
- Oves, M., Khan, M. S., Zaidi, A., Ahmed, A. S., Ahmed, F., Ahmad, E., Sherwani, A., Owais, M., & Azam, A. (2013). Antibacterial and cytotoxic efficacy of extracellular silver nano- particles biofabricated from chromium reducing novel OS4 strain of *Stenotrophomonas maltophilia*. *PLOS One*, 8(3), Article e59140. <https://doi.org/10.1371/journal.pone.0059140>
- Parikh, R. Y., Ramanathan, R., Coloe, P. J., Bhargava, S. K., Patole, M. S., Shouche, Y. S., & Bansal, V. (2011). Genus-wide physicochemical evidence of extracellular crystalline silver nano- particles biosynthesis by *Morganella* spp. *PLOS One*, 6(6), Article e21401. <https://doi.org/10.1371/journal.pone.0021401>
- Peiris, M. K., Gunasekara, C. P., Jayaweera, P. M., Arachchi, N. D. H., & Fernando, N. (2017). Biosynthesized silver nanoparticles: Are they effective antimicrobials? *Memórias do Instituto Oswaldo Cruz*, 112(8), 537–543. <https://doi.org/10.1590/0074-02760170023>
- Pourali, P., & Yahyaei, B. (2016). Biological production of silver nanoparticles by soil isolated bacteria and preliminary study of their cytotoxicity and cutaneous wound healing efficiency in rat. *Journal of Trace Elements in Medicine and Biology: Organ of the Society for Minerals and Trace Elements*, 34, 22–31. <https://doi.org/10.1016/j.jtemb.2015.11.004>
- Prakash, A., Sharma, S., Ahmad, N., Ghosh, A., & Sinha, P. (2011). Synthesis of Agnps By *Bacillus Cereus* Bacteria and Their Antimicrobial Potential. *Journal of Biomaterials and Nanobiotechnology*, 2(2), 155–161. <https://doi.org/10.4236/jbnb.2011.22020>
- Priyadarshini, S., Gopinath, V., Meera Priyadarshini, N., MubarakAli, D., & Velusamy, P. (2013). Synthesis of anisotropic silver nanoparticles using novel strain, *Bacillus flexus* and its bio- medical application. *Colloids and Surfaces. B, Biointerfaces*, 102, 232–237. <https://doi.org/10.1016/j.colsurfb.2012.08.018>
- Pugazhenthiran, N., Anandan, S., Kathiravan, G., Udaya Prakash, N. K., Crawford, S., & Ashokkumar, M. (2009). Microbial synthesis of silver nanoparticles by *Bacillus* sp. *Journal of Nanoparticle Research*, 11(7), 1811–1815. <https://doi.org/10.1007/s11051-009-9621-2>
- Punjabi, K., Yedurkar, S., Doshi, S., Deshapnde, S., & Vaidya, S. (2017). Biosynthesis of silver nanoparticles by *Pseudomonas* spp. isolated from effluent of an electroplating industry. *IET Nanobiotechnology*, 11(5), 584–590. <https://doi.org/10.1049/iet-nbt.2016.0172>
- Quinteros, M. A., Aiassa Martínez, I. M., Dalmasso, P. R., & Páez, P. L. (2016). Silver nanoparticles: Biosynthesis using an ATCC reference strain of *Pseudomonas aeruginosa* and activity as broad spectrum clinical antibacterial agents. *International Journal of Biomaterials*, 2016, Article 5971047. <https://doi.org/10.1155/2016/5971047>
- Railean-Plugaru, V., Pomastowski, P., Wypij, M., Szultka-Mlynska, M., Rafinska, K., Golinska, P., Dahm, H., & Buszewski, B. (2016). Study of silver nanoparticles synthesized by acidophilic strain of Actinobacteria isolated from the of *Picea sitchensis* forest soil. *Journal of Applied Microbiology*, 120(5), 1250–1263. <https://doi.org/10.1111/jam.13093>
- Rane, A. N., Baikar, V. V., Ravi Kumar, V., & Deopurkar, R. L. (2017). Agro-industrial wastes for production of biosurfactant by *Bacillus subtilis* ANR 88 and its application in synthesis of silver and gold nanoparticles. *Frontiers in Microbiology*, 8, 492. <https://doi.org/10.3389/fmicb.2017.00492>
- Rasulov, B., Rustamova, N., Yili, A., Zhao, H.-Q., & Aisa, H. A. (2016). Synthesis of silver nanoparticles on the basis of low and high molar mass exopolysaccharides of *Bradyrhizobium japonicum* 36 and its antimicrobial activity against some pathogens. *Folia Microbiologica (Praha)*, 61(4), 283–293. <https://doi.org/10.1007/s12223-015-0436-5>
- Rathod, D., Golinska, P., Wypij, M., Dahm, H., & Rai, M. (2016). A new report of *Nocardiosis* strain OT1 from alkaline Lonar crater of India and its use in synthesis of silver nanoparticles with special reference to evaluation of antibacterial activity and cytotoxicity. *Medical Microbiology and Immunology*, 205(5), 435–447. <https://doi.org/10.1007/s00430-016-0462-1>
- Rezvani Amin, Z., Khashyarmenesh, Z., & Fazly Bazzaz, B. S. (2016). Different behavior of *Staphylococcus epidermidis* in intracellular biosynthesis of silver and cadmium sulfide nanoparticles: More stability and lower toxicity of extracted nanoparticles. *World Journal of Microbiology and Biotechnology*, 32(9), 140. <https://doi.org/10.1007/s11274-016-2110-8>

- Sadhasivam, S., Shanmugam, P., & Yun, K. (2010). Biosynthesis of silver nanoparticles by *Streptomyces hygroscopicus* and antimicrobial activity against medically important pathogenic microorganisms. *Colloids and Surfaces. B, Biointerfaces*, 81(1), 358–362. <https://doi.org/10.1016/j.colsurfb.2010.07.036>
- Saifuddin, N., Wong, C. W., & Yasumira, A. A. N. (2009). Rapid biosynthesis of silver nanoparticles using culture supernatant of bacteria with microwave irradiation. *Journal of Chemistry*, 6(1), 61–70. <https://doi.org/10.1155/2009/734264>
- Samadi, N., Golkaran, D., Eslamifar, A., Jamalifar, H., Fazeli, M. R., & Mohseni, F. A. (2009). Intra/extracellular biosynthesis of silver nanoparticles by an autochthonous strain of *Proteus mirabilis* isolated from photographic waste. *Journal of Biomedical Nanotechnology*, 5(3), 247–253. <https://doi.org/10.1166/jbn.2009.1029>
- Saravana Kumar, P., Balachandran, C., Duraipandiyam, V., Ramasamy, D., Ignacimuthu, S., & Al-Dhabi, N. A. (2015). Extracellular biosynthesis of silver nanoparticle using *Streptomyces* sp. 09 PBT 005 and its antibacterial and cytotoxic properties. *Applied Nanoscience*, 5(2), 169–180. <https://doi.org/10.1007/s13204-014-0304-7>
- Saravanan, C., Rajesh, R., Kaviarasan, T., Muthukumar, K., Kavitha, D., & Shetty, P. H. (2017). Synthesis of silver nanoparticles using bacterial exopolysaccharide and its application for degradation of azo-dyes. *Biotechnology Reports*, 15, 33–40. <https://doi.org/10.1016/j.btre.2017.02.006>
- Sathiyarayanan, G., Seghal Kiran, G., & Selvin, J. (2013). Synthesis of silver nanoparticles by polysaccharide bioflocculant produced from marine *Bacillus subtilis* MSBN17. *Colloids and Surfaces, Part B: Biointerfaces*, 102, 13–20. <https://doi.org/10.1016/j.colsurfb.2012.07.032>
- Seshadri, S., Prakash, A., & Kowshik, M. (2012). Biosynthesis of silver nanoparticles by marine bacterium, *Idiomarina* sp. PR58-8. *Bulletin of Materials Science*, 35(7), 1201–1205. <https://doi.org/10.1007/s12034-012-0417-0>
- Shanthi, S., Jayaseelan, B. D., Velusamy, P., Vijayakumar, S., Chih, C. T., & Vaseeharan, B. (2016). Biosynthesis of silver nanoparticles using a probiotic *Bacillus licheniformis* Dahb1 and their antibiofilm activity and toxicity effects in *Ceriodaphnia Cornuta*. *Microbial Pathogenesis*, 93, 70–77. <https://doi.org/10.1016/j.micpath.2016.01.014>
- Singh, H., Du, J., & Yi, T.-H. (2017). Biosynthesis of silver nanoparticles using *Aeromonas* sp. THG-FG1.2 and its antibacterial activity against pathogenic microbes. *Artificial Cells, Nanomedicine, and Biotechnology*, 45(3), 584–590. <https://doi.org/10.3109/21691401.2016.1163715>
- Singh, P., Kim, Y. J., Singh, H., Mathiyalagan, R., Wang, C., & Yang, D. C. (2015). Biosynthesis of anisotropic silver nanoparticles by *Bhargavaea indica* and their synergistic effect with antibiotics against pathogenic microorganisms. *Journal of Nanomaterials*, 2015(1), 10. <https://doi.org/10.1155/2015/234741>
- Singh, P., Kim, Y. J., Wang, C., Mathiyalagan, R., & Yang, D. C. (2016). *Weissella oryzae* DC6-facilitated green synthesis of silver nanoparticles and their antimicrobial potential. *Artificial Cells, Nanomedicine, and Biotechnology*, 44(6), 1569–1575. <https://doi.org/10.3109/21691401.2015.1064937>
- Singh, P., Singh, H., Kim, Y. J., Mathiyalagan, R., Wang, C., & Yang, D. C. (2016). Extracellular synthesis of silver and gold nanoparticles by *Sporosarcina koreensis* DC4 and their biological applications. *Enzyme and Microbial Technology*, 86, 75–83. <https://doi.org/10.1016/j.enzmictec.2016.02.005>
- Singh, R., Shedbalkar, U. U., Wadhvani, S. A., & Chopade, B. A. (2015). Bacteriogenic silver nanoparticles: Synthesis, mechanism, and applications. *Applied Microbiology and Biotechnology*, 99(11), 4579–4593. <https://doi.org/10.1007/s00253-015-6622-1>
- Sintubin, L., De Windt, W., Dick, J., Mast, J., van der Ha, D., Verstraete, W., & Boon, N. (2009). Lactic acid bacteria as reducing and capping agent for the fast and efficient production of silver nanoparticles. *Applied Microbiology and Biotechnology*, 84(4), 741–749. <https://doi.org/10.1007/s00253-009-2032-6>
- Srivastava, S. K., & Constanti, M. (2012). Room temperature biogenic synthesis of multiple nanoparticles (Ag, Pd, Fe, Rh, Ni, Ru, Pt, Co, and Li) by *Pseudomonas aeruginosa* SM1. *Journal of Nanoparticle Research*, 14(4), 1–10. <https://doi.org/10.1007/s11051-012-0831-7>
- Syed, B., M N, N. P., B L, D., K, M. K., S, Y., & S, S. (2016). Synthesis of silver nanoparticles by endosymbiont *Pseudomonas fluorescens* CA 417 and their bactericidal activity. *Enzyme and Microbial Technology*, 95, 128–136. <https://doi.org/10.1016/j.enzmictec.2016.10.004>
- Tamboli, D. P., & Lee, D. S. (2013). Mechanistic antimicrobial approach of extracellularly synthesized silver nanoparticles against gram positive and gram negative bacteria. *Journal of Hazardous Materials*, 260, 878–884. <https://doi.org/10.1016/j.jhazmat.2013.06.003>
- Thomas, R., Janardhanan, A., Varghese, R. T., Soniya, E. V., Mathew, J., & Radhakrishnan, E. K. (2014). Antibacterial properties of silver nanoparticles synthesized by marine *Ochrobactrum* sp. *Brazilian Journal of Microbiology*, 45(4), 1221–1227. <https://doi.org/10.1590/s1517-83822014000400012>

- Tsibakhashvili, N. Y., Kirkesali, E. I., Pataraya, D. T., Gurielidze, M. A., Kalabegishvili, T. L., Gvarjaladze, D. N., Tsertsvadze, G. I., Frontasyeva, M. V., Zinicovscaia, I. I., Wakstein, M. S., Khakhanov, S. N., Shvindina, N. V., & Shklover, V. Y. (2011). Microbial synthesis of silver nanoparticles by *Streptomyces glaucus* and *Spirulina platensis*. *Advanced Science Letters*, 4(11), 3408–3417. <https://doi.org/10.1166/asl.2011.1915>
- Verma, S. K., Jha, E., Panda, P. K., Mishra, A., Thirumurugan, A., Das, B., Parashar, S. K. S., & Suar, M. (2018). Rapid novel facile biosynthesized Silver nanoparticles from Bacterial release induce biogenicity and concentration dependent in vivo cytotoxicity with embryonic zebrafish—A mechanistic insight. *Toxicological Sciences*, 161(1), 125–138. <https://doi.org/10.1093/toxsci/kfx204>
- Viorica, R.-P., Pawel, P., Kinga, M., Michal, Z., Katarzyna, R., & Boguslaw, B. (2017). *Lactococcus lactis* as a safe and inexpensive source of bioactive silver composites. *Applied Microbiology and Biotechnology*, 101(19), 7141–7153. <https://doi.org/10.1007/s00253-017-8443-x>
- Wang, C., Kim, Y. J., Singh, P., Mathiyalagan, R., Jin, Y., & Yang, D. C. (2016). Green synthesis of silver nanoparticles by *Bacillus methylothrophicus*, and their antimicrobial activity. *Artificial Cells, Nanomedicine, and Biotechnology*, 44(4), 1127–1132. <https://doi.org/10.3109/21691401.2015.1011805>
- Wang, C., Singh, P., Kim, Y. J., Mathiyalagan, R., Myagmarjav, D., Wang, D., Jin, C.-G., & Yang, D. C. (2016). Characterization and antimicrobial application of biosynthesized gold and silver nanoparticles by using *Microbacterium resistens*. *Artificial Cells, Nanomedicine, and Biotechnology*, 44(7), 1714–1721. <https://doi.org/10.3109/21691401.2015.1089253>
- Wypij, M., Golinska, P., Dahm, H., & Rai, M. (2017). Actinobacterial-mediated synthesis of silver nanoparticles and their activity against pathogenic bacteria. *IET Nanobiotechnology*, 11(3), 336–342. <https://doi.org/10.1049/iet-nbt.2016.0112>
- Yumei, L., Yamei, L., Qiang, L., & Jie, B. (2017). Rapid BioSyn-thesis of silver nanoparticles based on flocculation and reduction of an exopolysaccharide from *Arthrobacter* sp. *Journal of Nanomaterials*, 2017, 9703614, B4: its antimicrobial activity and phytotoxicity. <https://doi.org/10.1155/2017/9703614>
- Zaki, S., El Kady, M. F., & Abd-El-Haleem, D. (2011). Biosynthesis and structural characterization of silver nanoparticles from bacterial isolates. *Materials Research Bulletin*, 46(10), 1571–1576. <https://doi.org/10.1016/j.materresbull.2011.06.025>
- Zhang, H., Li, Q., Lu, Y., Sun, D., Lin, X., Deng, X., He, N., & Zheng, S. (2005). Biosorption and bioreduction of diamine silver complex by *Corynebacterium*. *Journal of Chemical Technology and Biotechnology*, 80(3), 285–290. <https://doi.org/10.1002/jctb.1191>